Abstract:Rapid developments in Regenerative Medicine and Tissue Engineering has witnessed an increasing drive toward clinical translation of breakthrough technologies. However, the progression of promising preclinical data to achieve successful clinical market authorisation remains a bottleneck. One hurdle for progress to the clinic is the transition from small animal research to advanced preclinical studies in large animals to test safety and efficacy of products. Notwithstanding this, to draw meaningful and reliable conclusions from animal experiments it is critical that the species and disease model of choice is relevant to answer the research question as well as the clinical problem. Selecting the most appropriate animal model requires in-depth knowledge of specific species and breeds to ascertain the adequacy of the model and outcome measures that closely mirror the clinical situation. Traditional reductionist approaches in animal experiments, which often do not sufficiently reflect the studied disease, are still the norm and can result in a disconnect in outcomes observed between animal studies and clinical trials. To address these concerns a reconsideration in approach will be required. This should include a stepwise approach using in vitro and ex vivo experiments as well as in silico modeling to minimize the need for in vivo studies for screening and early development studies, followed by large animal models which more closely resemble human disease. Naturally occurring, or spontaneous diseases in large animals remain a largely untapped resource, and given the similarities in pathophysiology to humans they not only allow for studying new treatment strategies but also disease etiology and prevention. Naturally occurring disease models, particularly for longer lived large animal species, allow for studying disorders at an age when the disease is most prevalent. As these diseases are usually also a concern in the chosen veterinary species they would be beneficiaries of newly developed therapies. Improved awareness of the progress in animal models is mutually beneficial for animals, researchers, human and veterinary patients. In this overview we describe advantages and disadvantages of various animal models including domesticated and companion animals used in regenerative medicine and tissue engineering to provide an informed choice of disease-relevant animal models.

Ex vivo functional whole organ in biomedical research: a review

Human organoids: model systems for human biology and medicine

Ex Vivo Intestinal Organoid Models: Current State-of-the-Art and Challenges in Disease Modelling and Therapeutic Testing for Colorectal Cancer

Vascularized Organoids: A More Complete Model

Insight to Biofabrication of Liver Microtissues for Disease Modeling: Challenges and Opportunities

In Vitro Models for the Study of Liver Biology and Diseases: Advances and Limitations

Whole Organ Engineering: Approaches, Challenges, and Future Directions

Organoid technology for tissue engineering

Ex Vivo Organ Cultures as Models to Study Bone Biology

Basic models to advanced systems: harnessing the power of organoids-based microphysiological models of the human brain

Application and challenge of pancreatic organoids in therapeutic research

Organoids in concert: engineering in vitro models toward enhanced fidelity

Organoid engineering with microfluidics and biomaterials for liver, lung disease, and cancer modeling

Role of animal models in biomedical research: a review

Organoid Models and Applications in Biomedical Research

Large Animal Models in Regenerative Medicine and Tissue Engineering: To Do or Not to Do

Adult Animal Stem Cell-Derived Organoids in Biomedical Research and the One Health Paradigm

Novel, Innovative Models to Study Ischemia/Reperfusion-Related Redox Damage in Organ Transplantation

Organoids as preclinical models of human disease: progress and applications

Organ Transplantation in Rodents: Novel Applications of Long-Established Methods

Exploring the prospects, advancements, and challenges of in vitro modeling of the heart-brain axis